Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

Viridian Shares Climb As Trial Data Reinforces Position In Thyroid Eye Disease Market

Viridian eye disease drug benefits chronic patients in late-stage trial

Why Is Viridian Therapeutics Stock Sinking Monday?

Viridian Therapeutics Stock Is Tanking. Why the Drop Is Linked to This Amgen Study.

Why Is Viridian Therapeutics Stock Falling Monday?

Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit

Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit

Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza